A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
← catalyst calendarNCT06858579 · readout in 865 d
Sponsored by Dianthus Therapeutics (industry) · DNTH — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
256estimated
Sites
188
Countries
Argentina, Australia, Belgium +26
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-10 | actual | When the study began enrolling |
| Primary completion | 2028-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
- Drug: Claseprubart — also filed as DNTH103
- Drug: Claseprubart — also filed as DNTH103
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPart B: Time From First Dose to Relapse as Assessed by the Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT)
measured Part B baseline to Part B end of treatment period (up to Week 52)
Permalink · DNTH's whole pipeline · Catalyst calendar · Every registered study · What changed